TORONTO, ONTARIO – CardioComm Solutions, Inc. (TSX VENTURE: EKG) (“CardioComm” or the “Company”), a leading global medical provider of consumer heart monitoring and electrocardiogram (“ECG”) acquisition and management software solutions,
announces
that it has begun work on a medical multiple biosignal monitoring platform that will support remote patient monitoring
(“RPM”) and telemedicine needs, including the use of wearable devices such as patches and wrist worn devices.
CardioComm recently secured an expanded ISO 13485:2016 MDSAP certification that permits the Company to grow its
operations solely from the development and sales of cardiac ECG monitoring software, hardware and ECG reading
services, to now include multiple health monitoring signals such as blood pressure, temperature, weight and P02.
The Company is a trusted provider of ECG monitoring solutions to hospitals, physician offices and remote patient
monitoring service providers. CardioComm is unique in its use of hospital ECG software in its consumer ECG product
offerings that are sold under the HeartCheck™ brand and SMART Monitoring ECG reading services. The expansion into
offering a platform with hardware and reviewing services for whole body biosignal monitoring is a logical progression.
CardioComm’s platform will address the need for adherence to critical characteristics absent in many remote patient
monitoring solutions offered today. These include, and are not limited to, compliance to a recognized quality
management system and ideally to the medical ISO 13485:2016 standard, a use of devices that are cleared as medical
devices for consumer use or under prescription use. This will ensure communication from multiple Bluetooth connected
devices are secure and that the whole platform supporting RPM is scalable and can support secure data collection and
data processing from thousands of monitored lives in near-real time.
CardioComm will provide updates on the new platform including expected FDA and Health Canada clearance applications
for new health monitoring devices that will be marketed under the HeartCheck™ brand. The first phase, which will
support ECG, blood pressure, temperature and P02 monitoring, is expected to be completed in Q1 2022. The Company
wishes to confirm that partial support for the first phase of this undertaking is provided through a grant from the NRC
Industrial Research Assistance Program (NRC-IRAP).
To learn more about CardioComm’s products and for further updates regarding HeartCheck™ ECG device integrations, please visit the Company’s websites at
www.cardiocommsolutions.com and www.theheartcheck.com.
